^
    Back
    Association details:
    Biomarker:BBOX1 underexpression
    Cancer:Renal Cell Carcinoma
    Drug:Rydapt (midostaurin) (Multi-tyrosine kinase inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    J Pathol Clin Res
    Title:

    Low gamma-butyrobetaine dioxygenase (BBOX1) expression as a prognostic biomarker in patients with clear cell renal cell carcinoma: a machine learning approach

    Published date:
    03/02/2023
    Excerpt:
    In vitro drug screening showed that midostaurin, BAY-61-3606, GSK690693, and linifanib inhibited the growth of RCC cells with low BBOX1 expression.
    DOI:
    10.1002/cjp2.315